Stay updated with breaking news from Alessandro Armuzzi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a "once in a career" result, study authors say.
![BRAT Diet For Diverticulitis: Is It Really Effective In [AU] 2023? - Vimarsana News](https://vimarsana.com/images/vimarsana-bigimage.jpg)
Are you considering the BRAT diet for diverticulitis? Find out the pros and cons of this particular diet for managing this condition in 2023.
Are you considering the BRAT diet for diverticulitis? Find out the pros and cons of this particular diet for managing this condition in 2023.
Are you considering the BRAT diet for diverticulitis? Find out the pros and cons of this particular diet for managing this condition in 2023.
Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib